CSPC Pharma's Clinical Data Presentations Could Be Near-Term Share Catalysts — Market Talk
CSPC Pharmaceutical's coming clinical data presentations over the next two months could serve as near-term share-price catalysts, say DBS Group Research's Mark Kong and Nico Chen in a note. The Chinese pharmaceutical group is scheduled to present on several key products, including Phase 3 clinical…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.